Product Description
Mechanisms of Action: ERBB3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Breakthrough Therapy - Lung Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung CancerPriority Review - Non-Small-Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Small Cell Lung Cancer|Head and Neck Cancer|Breast Cancer
Phase 1: Non-Small-Cell Lung Cancer|Lymphoma|Sarcoma|Breast Cancer|Small Cell Lung Cancer|Oncology Solid Tumor Unspecified|Head and Neck Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-121772 | P1 |
Completed |
Breast Cancer |
2018-12-31 |
|
| 2015-002222-40 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2018-02-21 |
|
| U31287-A-U203 | P2 |
Terminated |
Head and Neck Cancer|Squamous Cell Carcinoma |
2018-01-11 |
|
| JapicCTI-152841 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2016-12-31 |